Zealand Pharma
234.90 DKK
-36.38 %
Less than 1K followers
ZEAL
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-36.38 %
-41.19 %
-49.64 %
-53.76 %
-47.57 %
-57.68 %
-2.04 %
+22.92 %
+195.47 %
Zealand Pharma operates in biotechnology. Special focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest operations are in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Søborg, Denmark.
Read moreMarket cap
16.8B DKK
Turnover
833.56M DKK
Revenue
9.21B
EBIT %
75.52 %
P/E
2.57
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
All
Research
Press releases
ShowingAll content types
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity
Zealand Pharma convenes its Annual General Meeting 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools


